Marketing Approval, Presentation Schedules, Supplier Agreement, and Management Changes - Research Report on ImmunoGen, Endologix, Unilife, Sangamo, and Dynavax
NEW YORK, December 5, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting ImmunoGen, Inc. (NASDAQ: IMGN), Endologix, Inc. (NASDAQ: ELGX), Unilife Corporation (NASDAQ: UNIS), Sangamo Biosciences, Inc. (NASDAQ: SGMO), and Dynavax Technologies Corporation (NASDAQ: DVAX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
ImmunoGen, Inc. Research Report
On November 20, 2013, ImmunoGen, Inc. (ImmunoGen) announced that the European Commission has granted marketing approval for Kadcyla in the European Union (EU). The Company reported that the approval triggers a $5 million milestone payment to ImmunoGen. ImmunoGen further informed that Kadcyla has been approved by the European Commission for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received Herceptin and a taxane, separately or in combination. ImmunoGen further informed that upon approval, the timing of the commercial availability of Kadcyla in the EU and other international markets can vary due to national differences in processes for establishing pricing/reimbursement. The Full Research Report on ImmunoGen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/11c8_IMGN
Endologix, Inc. Research Report
On November 25, 2013, Endologix, Inc. (Endologix) announced participation in the Oppenheimer 24th Annual Healthcare Conference in New York. The event will be held on December 10, 2013 and Endologix is scheduled to present at 8:35 a.m. ET / 5:35 a.m. PT. The Full Research Report on Endologix, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/2f8d_ELGX
Unilife Corporation Research Report
On December 2, 2013, Unilife Corporation (Unilife) announced an agreement with Novartis to supply clinical products from one of its platforms of injectable drug delivery systems for use with one of Novartis' targeted early-stage pipeline drugs. Under the agreement, Unilife will supply Novartis with a customized delivery device to enable administration of a novel investigational Novartis drug into a targeted organ in clinical trials. Unilife further reported that the agreement grants Novartis an option for exclusivity. The Full Research Report on Unilife Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/90de_UNIS
Sangamo Biosciences, Inc. Research Report
On November 20, 2013, Sangamo Biosciences, Inc. (Sangamo) announced that seven abstracts have been accepted for presentation at the 55th annual meeting of the American Society of Hematology (ASH) from December 7 to December 10, 2013 in New Orleans, LA. "ASH provides an outstanding forum to highlight our advancing pre-clinical IND-candidate programs," said Edward Lanphier, President and CEO of Sangamo. "In particular, and for the first time, we will provide details of our ZFP Therapeutic approach to the treatment of sickle cell disease and b-thalassemia. Additionally, we will update on progress in our In Vivo Protein Replacement Platform (IVPRP), specifically our programs in hemophilia A and B. The ASH meeting also provides an excellent opportunity to highlight the breadth and depth of our ZFP Therapeutic platform. Data will also be presented from our activities in hematopoietic stem-cell manufacturing and applications in transplantation, as well as in zinc finger nuclease (ZFN) modified T-cells for oncology applications." The Full Research Report on Sangamo Biosciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/52a6_SGMO
Dynavax Technologies Corporation Research Report
On November 27, 2013, Dynavax Technologies Corporation (Dynavax) announced the resignation of J. Tyler Martin, M.D., from the Company's Board of Directors, effective at the end of 2013. The Company informed that Dr. Martin has been a director of the Dynavax since 2010 and has decided to resign to devote more time to his other professional responsibilities. Dynavax also informed that he is Founder and CEO of Great Plains Biotechnology. The Full Research Report on Dynavax Technologies Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/b180_DVAX
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
Share this article